AstraZeneca (NYSE: AZN) Reports Q2 2026 Earnings Before Market Open Monday July 27, 2026 With Core EPS of $2.63 (+18% Constant Currency, Beating $2.48 Consensus) on Revenue of $15.38 Billion (+5%, In Line With $15.39 Billion Consensus) and Advances Elecoglipron (Oral Small-Molecule GLP-1 Receptor Agonist) Into the Full Phase 3 Program in Q2 Across the EMBOLD Obesity Trials, the ELUMINATE Type 2 Diabetes Trials (Including Monotherapy and Combination With Dapagliflozin), and Cardiovascular and Kidney Outcome Trials Positioning AstraZeneca to Challenge Novo Nordisk and Eli Lilly in the Oral GLP-1 Market Alongside the Positive Q2 Update on Tozorakimab (Peak Sales Now Projected Above $5 Billion, Raised From $3 Billion)
AstraZeneca (NYSE: AZN) reported Q2 2026 earnings before market open Monday July 27, 2026 with core earnings per share of $2.63 for the three months ended June 30 (+18% constant currency), beating consensus of $2.48. Revenue of $15.38 billion was in line with consensus of $15.39 billion (+5%). Analyst focus on the earnings call centered on the pipeline update: elecoglipron, the oral small-molecule GLP-1 receptor agonist AstraZeneca in-licensed and advanced through Phase 2 VISTA and SOLSTICE (positive data at ADA 2026 Scientific Sessions in June), has moved into a full Phase 3 program in Q2 2026. The Phase 3 program includes the EMBOLD trials in adults with obesity or overweight (with and without type 2 diabetes), the ELUMINATE trials in adults with type 2 diabetes (as monotherapy and in combination with dapagliflozin), and long-term cardiovascular and kidney outcome trials. AstraZeneca is now the third major sponsor competing with Novo Nordisk and Eli Lilly for the oral GLP-1 market alongside oral semaglutide/Ozempic and orforglipron (Foundayo, FDA-approved April 2026). AstraZeneca separately revised the peak sales projection for tozorakimab (experimental respiratory treatment) to above $5 billion from the previous $3 billion estimate. AZN shares rose approximately 1.7% in London Monday morning trading.